Santa's Scorecard: Pharma

Valuation shifts reflect a combination of company-specific developments and broader market dynamics. In 2025, Pharma companies experienced a range of valuation movements, with some seeing their market value increase as strategies progressed, execution improved, or fundamentals strengthened. Others saw more modest or downward adjustments, often influenced by changing investor expectations or broader macroeconomic conditions. As we approach year-end, the following highlights some of the Pharma companies with the most notable changes in market capitalization in 2025.

Companies with the most valuation uplift in 2025:

↑ Eli Lilly and Company
↑ Johnson & Johnson
↑ Novartis
↑ AbbVie
↑ Roche
↑ AstraZeneca
↑ Gilead Sciences
↑ Amgen
↑ GSK
↑ Bayer

Companies with the most valuation pullback in 2025:

↓ Novo Nordisk
↓ CSL
↓ Zoetis
↓ Sanofi
↓ Pfizer